Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2020, with a report date of March 18, 2020. The filing discloses the vesting of awards under the 2009 Deferred Annual Bonus Plan (DABP) and associated Matching Awards for Persons Discharging Managerial Responsibilities (PDMRs), specifically Mr. B. McNamara, CEO of GSK Consumer Healthcare. The awards relate to a three-year performance period from January 1, 2017, to December 31, 2019.
Key Financial Metrics and Transaction Details
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics for the company. It focuses exclusively on executive compensation metrics and specific share transactions.
- Performance Metrics (2017-2019):
- Adjusted Free Cash Flow: Achieved £13bn (Target for maximum vesting: £12.95bn). Result: 100% vesting for this portion.
- Total Shareholder Return (TSR): Ranked 8th out of 10 comparator companies. Result: 0% vesting (below threshold).
- R&D New Products: Achieved £7.254bn in sales (Target for maximum vesting: £5.099bn). Result: 100% vesting for this portion.
- Total Vesting Outcome: 66.666% of the award vested; 33.334% lapsed.
- Share Transaction (Vesting): 4,005.955 ADSs released (2,391.955 Co-investment shares + 1,614 Matching Award shares) at $0.00 cost basis on March 16, 2020.
- Share Transaction (Tax Sale): 825 ADSs sold at $33.42 per share on the NYSE on March 16, 2020, to cover tax liabilities.
Material Changes and Performance Analysis
The filing details the outcome of the 2017 award cycle. While GSK exceeded targets for Adjusted Free Cash Flow and R&D New Product sales, it failed to meet the Total Shareholder Return threshold, resulting in a partial vesting of 66.666%. The closing price of an ADS on the vesting date (March 16, 2020) was $33.67.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. It is a regulatory disclosure strictly regarding the mechanics of executive compensation vesting and the subsequent sale of shares for tax purposes.
Key Facts for Investor Verification
- Verify the specific performance thresholds for the 2017-2019 period as disclosed in the 2018 Annual Report, which were adjusted from original targets.
- Confirm the impact of the 33.334% lapsed award portion on total executive compensation costs for the period.
- Note that the TSR metric resulted in zero vesting, indicating underperformance relative to the peer group of 10 global pharmaceutical companies during the 2017-2019 period.
- Verify the tax withholding calculation based on the sale of 825 ADSs at $33.42 against the total value of the vested Matching Award.